Table 1 Clinical characteristics of recurrent HGSC and breast cancer cohorts

Age at diagnosis

Gender

Mean

59.6

Male

0

1

Range

24.4–81.8

Female

13

19

Primary site

Age at diagnosis

Ovary

77

Mean

54.6

45.2

Peritoneum

24

Range

34–83

33–61

Female genital tract

4

Grade

Endometrium

1

1

0

2

Unknown

2

2

3

6

Grade

3

3

12

1

3

4

1

0

2

12

NA

6

0

3

71

Phenotype at diagnosis

Unknown

22

HR−, HER2−

1

4

Stage

HR+, HER2−

0

4

I

1

HR+, HER2+

12

2

II

2

HR−, HER2 NA

0

4

III

80

HR+, HER2 NA

0

1

IV

13

HR NA, HER2−

0

1

Unknown

12

HR NA, HER2+

0

1

Residual disease

NA

0

3

No macroscopic disease

20

Progression free survival

Macroscopic disease ≤1 cm

36

Number of events

13^a

20

Macroscopic disease > 1 cm

29

Median months

29

44

Macroscopic disease, size unknown

10

95% CI of median

8–50

18–90

Tumour not resected

6

NA

1

0

Unknown

7

Overall survival

Progression free survival

Number of events

13

18

Number of events

108

Median months

72

76

Median months

10.62

95% CI of median

34–172

43–139

95% CI of median

9.63–13.08

Germline mutation

Overall survival

BRCA1

0

4

Number of events

99

BRCA2

0

3

Median months

31.3

NA

13

13

95% CI of median

26.24–38.89

Sample collection procedure

Germline mutation

Biopsy

0

1

BRCA1

11

Excision

0

11

BRCA2

2

Autopsy

0

8

Lines of prior chemotherapy

Thoracentesis

13

0

Median

2

Prior treatment

Range

0–9

Median lines chemotherapy

5

1

Lines of prior MDR1 substrate chemotherapy

Range lines chemotherapy

1–8

0–4

Median

2

Median lines radiotherapy

2

1

Range

0–6

Range lines radiotherapy

0–4

0–2

Median lines targeted therapy

0

0

Range lines targeted therapy

0–6

0–2

Median lines hormone therapy

2

0

Range lines hormone therapy

0–5

0–1

Total cases

108

13

20